Clinical Research

My major interest in research is within the field of hepatobiliary and pancreatic disorders.

Clinical Research

Pancreatic Resection Techniques

Interested in methods of reducing the incidence of pancreatic fistula and techniques that reduce rates of delayed gastric emptying (Publication 42).Completed prospective study in examining the impact of Braun entero-enterotomy on delayed gastric emptying and pancreatic fistula (Publication 75).

Outcomes of Pancreaticoduodenectomy

Major interest in surgical outcomes of pancreaticoduodenectomy, in particular more advanced resections including additional organs and major venous resection (Publication 44, 45, 46, 92). Also interested in fast-track surgery after major pancreatic surgery.Compared fast-track surgery technique with standard techniques (Publication 76 and 83).

Pancreatic Cancer Treatment

Involved in a national study reviewing the outcomes of patients treated with borderline resectablepancreatic cancer.I am collaborating with oncology colleagues examining the role of gemcitabine combined with Abraxane for the treatment of pancreatic adenocarcinoma in a neoadjuvant and more recently adjuvant setting. I am also collaborating in a study assessing circulating tumour DNA as a marker of resectable pancreatic cancer, with colleagues at Royal Melbourne Hospital and Peter McCallum Cancer Center.

Screening for Pancreatic Cancer

Currently the lead investigator in Victoria of a pancreatic cancer screening program to screen individuals considered high risk for developing pancreatic cancer. This is in collaboration with colleagues at St Vincent’s Hospital (NSW) and the Gavan Institute (NSW).

Also, recently examined the association of diabetes and pancreatic cancer by meta-analysis. The study suggested that there may be a role for screening some patients with newly diagnosed diabetes for pancreatic cancer (Publication 91).

Postoperative Fluid Management

Collaborative work is being undertaken with the Department of Anaesthesia to determine optimal fluid management regimens in patients undergoing major liver and pancreas surgery (Publication 94).

Acute Pancreatitis

The impact of hyperbaric oxygen therapy on patients with severe necrotizing pancreatitis is being assessed. Apilot study was conducted.Treatment appears safe and may reduce disease severity when administered early following initial hospital presentation. (Publication 19).

Peri-Ampullary Tumours

Research has been conducted into treatment outcomes for peri-ampullarytumours. Particular focus is on the treatment outcomes for patients with ampullary adenocarcinomas. The potential role of local surgical therapies for these tumours is a subject of continuing research. (Publication 1)

Research in outcomes of patients with neuroendocrine pancreatic tumors conducted. Review of a large series of patients with pancreatic insulinomas treated at the Massachusetts general hospital and factors determining disease free recurrence was completed (Publication 34).

Colorectal Liver Metastases

Research into the long term survival of patients with unresectable colorectal liver metastases by laser thermotherapy has been conducted. In the initial series of 80 patients, treatment by laser thermotherapy improved survival, compared to the natural history of untreated disease. (Publication 15) A continuing prospective study is in progress.

Research into survival outcomes of patients in the era of effective chemotherapies and aggressive surgery has also been performed and is continuing (Publication 41).

Gallstones

Management of choledocholithiasis is an area of interest. A prospective study of selective endoscopic retrograde cholangiography in 427 patients with cholelithiasis was conducted. (Publication 14) The role of routine intra-operative cholangiography for the management of uncomplicated cholelithiasis is an area of continuing research. Assessment of outcomes of acute cholecystitis according the severity (Publication 66), age (Submitted) and gender (Publication 74) completed.

Endoscopic Retrograde Cholangiopancreatography

Prospective study of the effects of double wire cannulation on biliary cannulation success rates completed (Publication 82). Outcomes of metallic stenting for palliation of peri-ampullary malignancy published (Publication 69).

Post-Operative Pain Management

Interested in methods to reduce post-operative pain particularly following laparoscopic procedures. Participated in a randomized control trial that examined the efficacy of a depot long acting anaesthetic (Saber Bupivicaine)

Wound Infections

I am in interested in methods to reduce surgical site infection, in particular the role of pressurized irrigation devices to reduce wound infections (Publication 47). I am the principle investigator of a recently completed randomized trail assessing the impact of pulse irrigation on wound infections at the Austin and Warringal hospitals.

Diaphragm Pacing Stimulation

I am currently the only surgeon in Australasia that performs diaphragm pacing surgery for spinal cord injury and involved in research in this field (Publication 56 & 61). More recently the diaphragm pacing has been used selectively to prolong and improve quality of life in some patients with motor neurone disease (Publication 98).

Basic Research

Pancreas Cancer

A metastatic pancreatic cancer model using murine cells has been characterised in our laboratory (Publication 87). Studies are progress examining the role of P-21 Activated Kinases (PAKs) tin the treatment of pancreatic cancer. Pancreatic cancer develops as a result of a series of genetic mutations, and progresses from non- invasive tumours to invasive and metastatic cancers. The most frequent mutation, observed in more than 95% of cases, involve the K-Ras gene. The product of the K-Ras gene is a protein of 21 kDa (p21), which binds to and activates PAKs. The PAK family of serine/threonine kinases are not only important in carcinogenesis, but are also major regulators of cytoskeletal dynamics, with significant roles in cell proliferation and motility. PAKs are therefore an attractive therapeutic target, as PAK inhibitors should simultaneously block multiple pathways. We have for the first time published that reduction of PAK activity using a non-selective PAK inhibitor increases the sensitivity of PDAC to gemcitabine chemotherapy in vitro and in vivo (Publication 90). Ongoing studies are in progress to examine the role of PAKs (particularly PAK1 and PAK4) in the development, growth, chemosensitivity and survival of pancreatic cancer. This work is the subject of future major grant applications. . We plan to perform in vitro and in vivo studies with selective PAK1 and PAK4 inhibitors. In addition, as tumour-stroma interactions are extremely important in the development and progression of pancreatic cancer, these will be examined by utilisation of unique PAK knock-out murine models. The studies proposed in this application will elucidate the effects of targeting individual PAKs on the development and growth of pancreatic cancer, and may lead to the development of improved drug treatments. We are also collaborating the Garvan Institute NSW to look at the role of PAKs in the development of pancreatic cancer.

I have continuing involvement with pancreas cancer research in Australia, being a member of the Australian Pancreatic Cancer Genome Initiative (APCGI). Several pivotal publications have arisen form this collaborative effort (Publications 78,79,80,102)

Acute Pancreatitis

A rat model of acute severe pancreatitis was developed and characterized. The histological features of disease in this model are similar to the human situation. This involves retrograde injection of 4% Sodium Taurocholate into the biliopancreatic duct, under controlled pressure, to produce severe necrotizing pancreatitis. This model has been used to assess the effects of various therapies on the development of severe acute pancreatitis.

Hyperbaric Oxygen Therapy for the Treatment of Acute Severe Pancreatitis. Preliminary studies have been conducted into the potential use of hyperbaric oxygen (HBO) therapy to reduce the severity of severe acute pancreatitis. Compared to control animals with severe acute pancreatitis, HBO therapy appears to decrease pancreatitis severity and improve survival. Several studies have been completed and published.

Colorectal Liver Metastases

A mouse model of colorectal liver metastases has been used to research different treatment strategies for colorectal liver metastases. The model involves intrasplenic injection of a mouse derived colon cancer tumour line to induce liver metastases in CBA strain mice. The model closely resembles the human situation and has been characterized in terms of tumour growth patterns, blood vessel characteristics, histology and expression of various angiogenic markers. Direct comparisons to human colorectal liver metastases, in terms of histology and microvasculature have been undertaken. (Publication 11).

Interstitial Laser Thermotherapy of Liver Tumours. There is growing interest in the use of thermal ablation for the treatment of liver tumours. The mechanisms of tumour ablation by laser thermotherapy have been investigated in the previously described murine model of colorectal liver metastases. This has involved assessment of tumour injury following laser application by histology, immunohistochemistry and histochemical vital staining techniques. The effect of therapy on tumour microvasculature has been assessed by Laser Doppler Flowmetry, Scanning Electron Microscopy, Confocal in-vivo microscopy and oxygen fluorescence quenching techniques. The role of blood flow occlusion in the patterns of laser injury has been investigated. In addition, potential tumour growth promoting effects of thermal injury has been demonstrated. (Publications 4, 11, 12, 17, 20, 23, 24, 26-28)

Vascular Targeting of Colorectal Liver Tumours. The importance of tumour blood flow to the development of colorectal liver metastases and as a potential target for therapeutic interventions is a major research focus. The effect of thalidomide, as an anti-angiogenic agent, on the growth of colorectal liver metastases has been investigated. (Publications 22) Minor growth reducing effects have been shown. Several anti-tubulin binding agents that target intact tumour vasculature have been investigated and are under continuing research. These include Combretastatin A4 Phosphate Prodrug (Combretastatin A4P) and its derivatives and a recently developed agent, CYT997, showing major anti-tumour effects. In addition, macromolecular chemotherapeutic agents that are retained in tumours due the leakiness of tumour vessels and enhanced retention (Enhanced Permeability and Retention effect) have been investigated.

Reactive Oxygen Species Generation and Hyperbaric Oxygen Therapy. The potential synergistic use of reactive oxygen species (ROS) producing chemotherapeutics (SMA- Pirarubicin) and hyperbaric oxygen (HBO) therapy has been investigated for the treatment of colorectal liver metastases, with promising results. Further studies into the effects of ROS and HBO on turmour growth are in progress.

Liver Regeneration and Tumour Growth. A novel technique of liver resection in mice was developed and used to asses the effects of liver regeneration on the growth of colorectal liver metastases. (Publication 16) Following major liver resection growth promoting effects have been demonstrated, including increased incidence of extrahepatic tumour spread. The mechanisms involved in the growth promoting effects are under investigation.

Ischameia Perfusion Study

Currently involved in a study examining the neuronal changes that occur as result of small bowel ischaemia utilizing human tissues obtained at the time of major pancreatic surgery. The role of nitric Oxide in enteric ischemic damage is being assessed.

Cholangiocarcinoma

Studies examining the examining the role of targeting the mTOR pathway in biliary tract carcinoma is ongoing in collaboration with Prof J Mariadason at the Olivia Newton John Cancer institute.

Thesis Summary

"The Effect of Laser Induced Thermal Ablation on Liver Tumours"
Doctorate of Philosophy by Thesis, University of Melbourne

Background

Laser thermal ablation (LTA) is an in situ ablative technique that induces heat destruction of liver tumours. Despite increasing clinical use of LTA, reports of long-term outcomes and limitation of treatment in specific cohorts of patients with liver tumours are lacking. In addition, the mechanisms of action of therapy have not been fully elucidated.

This study highlights the long-term clinical results and limitations of LTA in the treatment of a cohort of patients with unresectable colorectal liver metastases and examines the mechanisms of action thermal ablative injury in a murine model.

Methods

In 80 patients with unresectable colorectal cancer (CRC) liver metastases treated by LTA using Nd-YAG laser (wavelength 1064 nm) with ultrasound real-time monitoring, long-term treatment efficacy was assessed. Patients were selected based on the following criteria: (1) Disease confined to the liver (2) Unsuitable for complete surgical resection due to anatomical location of tumours or the extent of hepatic involvement (3) Maximum of five tumours and (4) Tumour diameter not exceeding 10 cm.

The mechanism of thermal ablative injury was assessed in a murine model of colorectal liver metastases. Laser (2 Watts for 50 seconds) was applied to the liver and tumours in CBA strain mice. Tissue injury was assessed at varying time points ranging from immediately following injury to 21 days thereafter. The extent of thermal injury was assessed histochemically by a vital stain for nicotinamide adenine dinucleotide (NADH) diaphorase. Tissue sections were also studied by immunohistochemistry for apoptosis, Kupffer cell response and heat shock protein 70 (HSP 70) expression. Microvascular damage was assessed at various time points by scanning electron microscopy, Laser Doppler flowmetry and confocal in-vivo microscopy.

Potential growth promoting effects of laser therapy on micrometastases was assessed following 30% liver volume ablation in animals bearing microscopic colorectal liver metastases. The volume of tumour growth in the regenerating ablated liver lobe was compared to untreated lobes and controls by tumour stereology. Tumour proliferation was determined by immunohistochemistry for Ki67 antigen. The effect of thermal ablation was assessed in a separate group of animals on the induction of angiogenic factors, Vascular endothelial Growth factor (VEGF), Fibroblast growth factor (FGF), and Transforming Growth factor B (TGF beta) was assessed by immunohistochemistry.

Results

In our clinical study of 80 patients, 168 liver tumours were treated by LTA with a median diameter of 5 cm (range 1 – 10 cm) without any procedure related deaths. The overall complication rate was 16%, with all cases managed conservatively. Complete tumour ablation was achieved in 67% of patients. Sixty-seven deaths occurred and were related to hepatic recurrences in 55 cases, extrahepatic disease in 9 patients and unrelated to malignancy in 3 others. The median survival of patients treated by LTA was 35 months, with a 5-year survival of 6.7%.

Thermal ablation produces direct lethal thermal injury followed by indirect progressive tissue damage beyond the initial thermal effects. Normal liver and tumour tissue respond differently to thermal ablation. In tumour tissue the direct injury is more pronounced, while the progression of injury is more rapid and extensive in liver. In liver, the peak volume of necrosis occurred at 3 days, while in tumour tissue the peak was at 4.5 days.

Increased apoptotic response was noted at 12 hours following thermal injury and remained elevated until 72 hours in tumour tissue. HSP 70 expression was most pronounced in tumour tissue and remained elevated for 72 hours following therapy. Stimulation of Kupffer cell activity occurred in both liver and tumour tissue. The increase in Kupffer cell activity is earlier and greater in liver tissue. Progressive microvascular injury was observed following thermal ablation in both liver and tumour tissue and at times preceded the tissue injury.

In animals with micrometastases, 30% ablation of liver volume by laser produced an increase in percentage of tumours in the regenerating lobe, without an overall increase in tumour load or extrahepatic spread. Following thermal ablation, there was increased local expression of VEGF and FGF in liver and increased expression of VEGF, FGF and TGF in tumour adjacent to the treatment site.

Conclusion

Overall, treatment of selected patients with liver tumours by LTA appears to achieve long-term survival. There is however a high incidence of local tumour recurrence due to incomplete tumour destruction and regional and extrahepatic tumour recurrences. Thermal ablation by laser produces direct injury followed by indirect effects that results in progressive tissue damage and involves interplay of several factors. Thermal ablation by laser appears to have local tumour promoting effects, possibly related to increased induction of several angiogenic factors. Manipulation of the processes involved in laser induced tumour destruction may further ensure complete tumour destruction and reduce local and distal recurrences.

Research Grants

Awarded by Peer Review

Surgeon Scientist Scholarship 2002–2004 – Royal Australasian College of Surgeons "Treatment of liver tumours"
Nikfarjam M

Equity Trustees - Harold Brennen Foundation 2003
"Treatment of liver tumours by focal hyperthermia"
Christophi C, Nikfarjam M

Jack Brockhoff Foundation 2003
"Treatment of liver tumours"
Christophi C, Nikfarjam M

Austin Hospital Medical Research Foundation 2004
"Hyperbaric oxygen therapy for the treatment of severe pancreatitis"
Christophi C, Nikfarjam M

Astra Zenica Project Grant 2005
"The mechanisms of focal hyperthermia on colorectal cancer liver metastases"
Christophi C, Nikfarjam M

University of Melbourne Research Grant 2005
"Treatment of liver tumours by thermal ablation"
Christophi C, Muralidharan V, Shulkes A, Nikfarjam M

University of Melbourne Research Grant 2006
"Hyperbaric oxygen therapy for the treatment of acute severe pancreatitis"
Christophi C, Millar I, Muralidharan V, Shulkes A, Nikfarjam M

Anti-cancer Council of Australia Project Grant 2006
"Treatment of liver tumours by thermal ablation"
Christophi C, Muralidharan V, Shulkes A, Nikfarjam M

Early Career Grant – University of Melbourne 2010
“Wound Irrigation Study”
Nikfarjam M

Austin Research Medical Foundation – Austin Health 2012
“Role of PAK in pancreatic cancer"
Nikfarjam M

Austin Research Medical Foundation – Austin Health 2013
“Role of P21-activated kinases (PAK) in determining sensitivity of pancreatic carcinoma to gemcitabine chemotherapy”
Nikfarjam M $18,000

Victorian Cancer Agency 2014
“Targeting the mTOR pathway in biliary tract carcinoma”. Chief Investigator A/Prof John Mariadason. Co-investigators M Nikfarjam, N Tebbutt, D Groagh, O Sierber
$641,000

Sir Edward Dunlop Medical Research Foundation Grant 2014
“Role of P21-activated kinases (PAK) in Pancreatic cancer”
Nikfarjam M $20,000

Austin Research Medical Foundation – Austin health 2015
“PAK as a prognostic marker in pancreatic cancer Nikfarjam M $15,000

Pancare Foundation – 2015
“Accelerating research into the treatment of pancreatic cancer by use of novel agents” Baldwin and Nikfarjam $100,000

NHMRC 2016
Overcoming therapeutic resistance in pancreatic cancer. CIA Putoczki T $924,901
AI: Nikfarjam M

Pancare Foundation – 2016-2017
“Improving the treatment of pancreatic cancer by novel treatment targets” Nikfarjam $419,356

Avner Foundation – 2017 Innovation Grant
Utilising a novel predictor to stratify patients with therapy-resistant pancreatic cancer for treatment with CHK inhibitor drugs to improve responses and outcomes. CIC
$96,986

Austin Research Medical Foundation – Austin health 2018
The Role of P21-Activated Kinases in the Development of Pancreatic cancer
$12,500

University of Melbourne Grant Scheme 2018
To determine the role of P21-Activated Kinases (PAKs) in the development of pancreatic ductal adenocarcinoma Nikfarjam M $50,000

Pancare Foundation – 2019
Improving the treatment of pancreatic cancer by novel treatment targets including studying the role of cannabinoids. $150,000

Tour De Cure/ Pancare Foundation 2019
Improving the Pancreatic Cancer outcomes through Novel Treatment Targets $50,000

Presentations

International

  1. “SMA-Pirarubicin and combined with hyperbaric oxygen therapy for the treatment of colorectal liver metastases”. Undersea and hyperbaric medicine conference, Sydney, Australia 2004  Millar I, Nikfarjam  M, Christiophi C.
  2. “A new miceller anticancer drug: In vivo and in vitro evaluation of SMA-Pirarubicin micelles”. Controlled release annual society meeting, USA 2004 Maeda H, Greish K, Nikfarjam M, Christophi C.
  3. “Improved Survival following interstitial laser thermotherapy for the treatment of unrespectable colorectal liver metastases”. AASLD, Boston, USA 2004 Nikfarjam M, Christophi C.
  4. “Mechanisms of liver tumour ablation by focal hyperthermia”. AASLD, Boston, USA 2004 Nikfarjam M, Christophi C.
  5. Thalidomide for the treatment of colorectal liver metastases. AGW, Brisbane, Australia 2004 Darawalla J, Nikfarjam M, Christophi C.
  6. “Oxi4503 for the treatment of colorectal liver metastases”. AGW, Brisbane, Australia 2004 Malcontenti-Wilson C, Nikfarjam M, Christophi C.
  7. “Altered patterns of tumor growth following focal hyperthermia”. DDW, Chicago, USA 2005 Nikfarjam M, Christophi C.
  8. “Hyperbaric oxygen reduces morbidity and mortality in severe acute pancreatitis”. International Conference on Diving and Hyperbaric Medicine, Barcelona, USA 2005 Millar I, Nikfarjam M, Christophi C.
  9. “Improved Contemporary Surgical Management of Insulinomas: A 25-year Experience at the Massachusetts General Hospital.”. American Pancreatic Association, USA 2007 Nikfarjam M, Warshaw AL, Axelrod, L, Deshpande V, Thayer SP, Ferrone CR, Fernández-del Castillo C
  10. “Immunologic ignorance and tolerance both play a role in hepatic tumorigenesis” Digestive Diseases Week, USA 2008, Avella D, Nikfarjam M . Staveley-O’Carroll.
  11. “ Surgical outcomes of patients with gastrointestinal stromal tumors in the era of target drug therapy” Digestive Diseases Week, USA 2008, Nikfarjam M . Staveley-O’Carroll.
  12. “Alloderm Mesh: An Innovative Tool for Diaphragmatic Reconstruction in Patients with large retroperitoneal Sarcomas”. Association for Academic Surgery (AAS). 3rd Annual Academic Surgical Congress. 2008. Huntington Beach. CA. Avella D, Nikfarjam M . Staveley-O’Carroll
  13. “Surgical Management of Liver Metastasis” Advances in the Management of Colorectal Cancer (Invited lecture). Colorectal Cancer Symposium, Pennsylvania 2008. Nikfarjam M
  14. “Magnetic resonance imaging is a powerful tool for characterizing the impact of radiofrequency ablation in a murine model of spontaneous hepatocellular cancer” AHBPA 2008 Shereef S. Nikfarjam M. . Staveley-O’Carroll
  15. “Combined pancreaticoduodenectomy and right hemicolectomy – Outcomes and Indications”. American Pancreatic Association, USA 2008 Kimchi E. Nikfarjam M, . Staveley-O’Carroll KF
  16. “Reduced Delayed Gastric Emptying with Non-pylorus Preserving Pancreaticoduodenectomy and Antecolic Gastrojejunal Anastomosis” American Pancreatic Association, USA 2008 Gusani NF, Nikfarjam M, . Staveley-O’Carroll KF
  17. “Reduction of surgical site infections by use of pulsatile lavage irrigation device after prolonged intra-abdominal operative procedures ”. Annual Academic Surgical Congress USA 2009. Nikfarjam M... Staveley-O’Carroll.
  18. “The Diagnostic Efficacy of Natural Orifice Endoscopic Surgery (NOTES): Is there a Role in the Intensive Care Unit? SAGES USA 2009 Trunzo, J. Nikfarjam M ..  Marks JM. 
  19. “Examination of the Local Inflammatory Response of NOTES (Natural Orifice Translumenal Endoscopic Surgery) Versus Laparoscopy Utilizing Both Carbon Dioxide and Room Air in a Porcine Model” SAGES USA 2009 Trunzo, J. Nikfarjam M .. Marks JM.
  20. “Pancreaticoduodenectomy in patients with a history of Roux-en Y gastric bypass surgery” Pancreas Club USA 2009 Nikfarjam M, Hardcare J.
  21. “Additional organ resection combined with pancreaticoduodenectomy does not increase post-operative morbidity and mortality”. AHPBA USA 2009 Nikfarjam M, . Staveley-O’Carroll
  22. “Peri-pancreatic Castleman’s disease” Annual Academic Surgical Congress USA 2009 Shereef S, Nikfarjam M .. Staveley-O’Carroll KF
  23. “The effect of surgical volume and the provision of residency and fellowship training on complications of major hepatic resection” AHPBA/IHPBA Argentina 2010 Nikfarjam M and Kohn G.
  24. “Outcomes of contemporary management of gangrenous and non-gangrenous acute cholecystitis” DDW USA 2011
  25. Management of duodenal diverticulum. APHPBA Australia 2011 (Invited talk)
  26. . Laparoscopic distal pancreatectomy. APHPBA Australia 2011 (Invited talk)
  27. Update in NOTES cholecystectomy. APHPBA Australia 2011 (Invited talk)
  28. Laparoscopic ligation of common hepatic artery to precondition liver and stomach prior to radical distal pancreatectomy and splenectomy with enbloc resection of the celiac axis for locally advanced pancreatic body/ tail tumors APHPBA Australia 2011 Houli N & Nikfarjam M
  29. Fluid sparing regimens in surgery Perioperative medicine Conference - ANZCA annual meeting, NSW Australia 2012 (Invited talk)
  30. Fast track recovery following pancreaticoduodectomy. Australia and New Zealand pancreas club, SA Australia 2012
  31. A novel p21-activated kinase 1 inhibitor, Glaucarubinone, combined with Gemcitabine synergistically inhibits the growth of pancreatic ductal adenocarcinoma. Pancreas Club, Orldando, Florida, USA 2013
  32. Advances in Pancreatic surgery (invited talk) Australasian Pancreas Club, Melbourne, Victoria Australia 2013
  33. Association of Diabetes Mellitus and Pancreatic Adenocarcinoma-
    A Meta-analysis of 86 Studies. Australasian Pancreas Club, Melbourne, Victoria Australia 2013
  34. Potential role of PAK4 in treatment of pancreatic cancer Australasian Pancreas Club, Melbourne, Victoria, Australia 2013
  35. Glaucorubinone for the treatment of pancreatic ductal adenocarcinoma Australasian Pancreas Club, Melbourne, Victoria Australia 2013
  36. A multicentre randomized double-blind controlled non-inferiority multicentre study of Plasmalyte vs. Compound Lactate Solution in patients undergoing liver resection. Australian & New Zealand College of Anaesthetists Annual Scientific Meeting, Melbourne, Victoria, Australia 2013
  37. Analgesia practice for pancreaticoduodenectomy (Whipple’s Procedure): Is it time to reconsider epidurals? Australian & New Zealand College of Anaesthetists Annual Scientific Meeting, Melbourne, Victoria, Australia 2013
  38. Enhanced Recovery After Surgery Program Reduces Length of Stay Following Uncomplicated Pancreaticoduodenectomy. Australian & New Zealand College of Anesthetists Annual Scientific Meeting, Melbourne, Victoria, Australia 2013
  39. Liberal fluid intervention and positive fluid balance affect length of hospital stay following pancreaticoduodenectomy Australian & New Zealand College of Anesthetists Annual Scientific Meeting, Melbourne, Victoria, Australia 2013
  40. Sodium bicarbonate infusion does not prevent acute kidney injury in patients undergoing orthotopic liver transplantation: a single-centre prospective phase 2 blinded randomized controlled trial Australia & New Zealand College of Anaesthetists ASM and Royal Australasian College of Surgeons Annual Scientific Congress, Sans Expo and Convention Centre, 5-9th Singapore May 2014
  41. Impact of a surgery-specific goal directed therapy protocol in reducing major complications in patients undergoing pancreaticoduodenectomy (Whipple’s procedure) Australia & New Zealand College of Anaesthetists ASM and Royal Australasian College of Surgeons Annual Scientific Congress, Sans Expo and Convention Centre, 5-9th Singapore May 2014.
  42. A p21-Activated Kinase 1 Inhibitor, FRAX-597, Combined with Gemcitabine Synergistically Inhibits the Growth of Pancreatic Ductal Adenocarcinoma Australasian Pancreas Club, Melbourne, Victoria, Australia 2014
  43. Pancreatic cancer. Congress session Chair. GASTRO 2015 GESA-AGW & WGO INTERNATIONAL CONGRESS 2015
  44. Targeting PAK1 in pancreatic cancer stellate cells increases survival GASTRO 2015 GESA-AGW & WGO INTERNATIONAL CONGRESS 2015
  45. Combination of pan-PAK inhibitor (PF3758309) with gemcitabine synergistically reduce PDAC growth and migration. Dr Kai Wang.  Australasian Pancreatic Club. November 12-13th 2016
  46. Age 80 years and over is not associated with increased morbidity and mortality following pancreaticoduodenectomy. Ms Sandy Kim. Australasian Pancreatic Club. November 12-13th 2016
  47. Targeting PAK1 in Pancreatic Stellate Cells Increases Pancreatic Cancer Survival Pancreas Club. San Diego, USA. May 20th-21st 2016.
  48. Targeting PAK1 in Pancreatic Stellate Cells Increases Pancreatic Cancer Survival. Pancreas2016, Glasgow, UK.  June 9th-12th 2016.
  49. Inhibition of p21 activated kinases enhances chemo-therapeutic effects of multiple reagents on patient’s derived pancreatic cancer cell lines. Cold Spring Harbor Asia, Suzhou, China.  Precision Cancer Biology from Targeted to Immune Therapies.  Sept 18-22 2017 
  50. Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and postoperative management of localised pancreatic cancer. ASCO USA 2017
  51. Fluid optimisation algorithm improves outcomes in patients undergoing pancreaticoduodenctomy: a prospective multicentre randomised controlled trial. . Pancreas Club, Chicago USA 2017
  52. Outcomes of central hepatectomy versus extended hepatectomy. ANZHPBA Meeting 2017
  53. A novel predictor for stratifying pancreatic cancer patients to DNA damage checkpoint inhibitors. 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, Netherlands 2018
  54. PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine + nab-paclitaxel (GNP) chemotherapies. ASCO USA 2019
  55. Exploring Cannabis medicines for Pancreatic cancer treatment (Invited talk) 2019 UIC Australian Medical Cannabis Symposium 22nd March – 24th March 2019

National and State

  1. “The role of local resection in the treatment of ampullary tumours of the duodenum”. RACS Victorian Annual Scientific meeting, Shepperton Australia 2000 Nikfarjam M.
  2. “The role of endoscopic ultrasound in the treatment of ampullary tumours of the duodenum”. Cabrini Institute, Melbourne, Australia 2000 Nikfarjam M.
  3. “Management of ampullary tumours”. Gut Club, Melbourne, Australia 2002 Nikfarjam M.
  4. “Progressive necrosis occurs independent of thermal effects following laser thermal ablation”.  Annual Scientific Meeting, Melbourne, Australia 2003 Nikfarjam M.
  5. “SMA- Pirarubicin for the treatment of colorectal liver metastases”. RACS Victorian Annual Scientific meeting, Bendigo, Australia 2004 Nikfarjam M.
  6. “Hyperbaric Oxygen therapy for the treatment of acute severe pancreatitis”. Cabrini Institute, Melbourne, Australia 2004 Nikfarjam M.
  7. “NOTES in HPB Surgery” Langham Meeting, Melbourne, Australia 2009 (Invited Talk)
  8. “Career development – Training in the USA” – Victorian Scientific Meeting, Melbourne 2010 (Invited Talk)
  9. “Specialist Surgeon versus Generalist” Victorian Scientific Meeting, Melbourne 2010 (Invited Talk)
  10.  “NOTES – A note of caution” Gut Club, Melbourne 2010 (Invited Talk
  11.  “Current management of colorectal liver metastases” Roche Medical, Melbourne 2010 (Invited talk)
  12.  Management of pancreatic pseudocysts  3rd Annual Cook Medical Pancreatico-Biliary Workshop.  Sydney, NSW 2013 (invited talk)
  13.  Cystic Tumours of the pancreas.  4th Annual Cook Medical Pancreatico-Biliary Workshop.  Sydney, NSW 2013 (invited talk)
  14.  Pancreatic Neuroendocrine liver metastases – A management approach.  Victorian endocrine meeting. St Vincent’s Hospital, Melbourne, Australia 2013 (invited talk)
  15.  A multifaceted approach to taking up the challenge against pancreatic cancer. Australian Pancreatic Cancer Genome Initiative 2014  Garvan Institute NSW (invited talk)
  16.  Pancreatic cyst management guidelines – (Panel)  5th Annual Cook Medical Pancreatico-Biliary Workshop.  Sydney, NSW 2014 (invited talk)
  17. P21-Activated Kinases for the treatment of Pancreatic cancer Monash Institute of Pharmaceutical Science Pancreatic Mini Symposium 8/4/2015  2015 (Invited talk)
  18. Pancreatic cancer Interactive session– (Panel)  6th Annual Cook Medical Pancreatico-Biliary Workshop.  Sydney, NSW 2015
  19.  Familial Pancreatic cancer Screening 27th July 2015.  Familial Cancer Center, Peter MacCallum Cancer Center, Melbourne Australia Symposium (Invited)
  20. P-21 Activated Kinase inhibition combined with chemotherapy improves treatment of pancreatic ductal adenocarcinoma. October 6th 2015. University of Melbourne Research Seminar. 2015
  21. P-21 Activated Kinase Inhibition for the treatment of pancreatic cancer.  Sir Edward Dunlop Symposium,  Austin Health, Melbourne,  October 26th 2016
  22. The role of p-21-activated kinases in pancreatic ductal adenocarcinoma, University of Melbourne, Royal Melbourne Hospital, Melbourne, November 9th 2016.
  23. Animals models in pancreatic cancer. Pancreatic cancer; Registries, Trials and Translational Research. Walter and Eliza Hall Institute July 19th 2017.

Publications

  1. Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014 Jul;21(7):2453-62..
  2. Iorgulescu DG, Ling S, Nikfarjam M, Fink MA, Jones R, Muralidharan V, Starkey G, Christophi C. Results of pancreatic resection associated with portal vein resection in an Australian tertiary care centre. ANZ J Surg. 2014 Apr 9. doi:
  3. Nikfarjam M, Low N, Weinberg L, Chia PH, He H, Christophi C. Total pancreatectomy for the treatment of pancreatic neoplasms. ANZ J Surg. 2014 Apr 22.
  4. Weinberg L, Wong D, Karalapillai D, Pearce B, Tan CO, Tay S, Christophi C, McNicol L, Nikfarjam M The impact of fluid intervention on complications and length of hospital stay after pancreaticoduodenectomy (Whipple's procedure). BMC Anesthesiol. 2014 May 14;14:35
  5. Cho HJ, Robinson ES, Rivera LR, McMillan PJ, Testro A, Nikfarjam M, Bravo DM, Furness JB. Glucagon-like peptide 1 and peptide YY are in separate storage organelles in enteroendocrine cells.Cell Tissue Res. 2014 Jul;357(1):63-9
  6. Weinberg L, Faulkner M, Tan CO, Liu DH, Tay S, Nikfarjam M, Peyton P, Story D. Fluid prescription practices of anesthesiologists managing patients undergoing elective colonoscopy: an observational study. BMC Res Notes. 2014 Jun 10;7:356.
  7. Dudi-Venkata NN, Houli N, Weinberg L, Nikfarjam M. Laparoscopic partial splenectomy performed by monopolar saline-cooled radiofrequency coagulation. J Laparoendosc Adv Surg Tech A. 2014 Jul;24(7):502-5.
  8. Yeo D, He H, Baldwin G, Nikfarjam M. The Role of p21-Activated Kinase in Pancreatic Cancer. Pancreas. 2015 Apr;44(3):363-9
  9. Bhandari R, Riddiough G, Lokan J, Weinberg L, Efthymiou M, Nikfarjam M. Somatostatinoma of the minor papilla treated by local excision in a patient with neurofibromatosis type 1. JOP. 2015 Jan 31;16(1):81-4
  10. Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Nikfarjam M Pearson JV, Biankin AV, Grimmond SM Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015 Feb 26;518(7540):495-501.
  11. Weinberg L, Peake B, Tan C, Nikfarjam M. Pharmacokinetics and pharmacodynamics of lignocaine: a review. World Journal Issue date: 2015-07-29 17:02
  12. Chen H, Teague J, Weinberg L,   Nikfarjam Diffuse Pancreatic Mucinous Cystic Neoplasm Treated by Total Pancreatectomy.  JOP 2015 16(3):295-298
  13. Weinberg L, Spanger M, Tan C, Nikfarjam M. Postoperative wristwatch-induced compressive neuropathy of the hand: a case report. J Med Case Rep. 2015 Jun 16;9:141
  14. Lau L, Christophi C, Nikfarjam M, Starkey G, Goodwin M, Weinberg L, Ho L, Muralidharan V. Assessment of Liver Remnant Using ICG Clearance Intraoperatively during Vascular Exclusion: Early Experience with the ALIIVE Technique. HPB Surg. 2015;2015:757052. doi: 10
  15. Smith R, Smith S, Wilson J, Pearce C, Wray N, Vo R, Chen J, Ooi K, Oliver M, Katz T, Turner R, Nikfarjam M, Rayner C, M Horwitz, Pirola R, Neale R, Windsor R. Summary and Reccomendations of the Australian Guidelines for the management of pancreatic enzyme insuffiency. Pancreatology. 2015 (In Press)
  16. Adams J, Marbini HD, Nikfarjam M, Howard M, Atkins N, Story D Anesthesia for inserting diaphragmatic pacing for motor neurone disease (Two Case Reports)," Advances in Anesthesiology 2016 (in Press)
  17. Weinberg L, Pearce B, Sullivan R, Siu L,  Scurrah N,  Story D, Backstrom M,  Nikfarjam M,  McNicol  L, Christophi C, Bellomo Plasmalyte-148 improves biochemistry, coagulation and complication rates in patients undergoing open liver resection when compared with Hartmann’s solution. Minerva Anesthesiologica 2014 Nov 19 (Epub Ahead of Print).
  18. Chandrasegaram M, Goldstein D, Simes  J,  Gebski V, Kench  J,  Gill Samra J,  Merrett N,  Richardson A,  Barbour A, Fawcett J,   Grimison P , Christophi C,  Padbury R, Haghighi K,  Chen,  Nikfarjam MO'Rourke N,  Spry N, · Meta-analysis of radical resection rates and margin assessment in pancreatic cancer Br J Surg. 2015 Nov;102(12):1459-72
  19. Yeo D, He H, Patel O, Lowy A, Baldwin G, Nikfarjam M. FRAX597, a PAK1 Inhibitor, Synergistically Reduces Pancreatic Cancer Growth when Combined with Gemcitabine BMC cancer 2016 (in Press)
  20. Weinberg L, Broad J, Pillai P, Chen G, Nguyen M, Eastwood GM, Scurrah N, Nikfarjam M, Story D, McNicol L, Bellomo R. Sodium bicarbonate infusion in patients undergoing orthotopic liver transplantation: a single centre randomized controlled pilot trial.Clin Transplant. 2016 Feb 23. doi: 10.1111/ctr.12721
  21. Working Party of the Australasian Pancreatic Club, Smith RC, Smith SF, Wilson J, Pearce C, Wray N, Vo R, Chen J, Ooi CY, Oliver M, Katz T, Turner R, Nikfarjam M, Rayner C, Horowitz M, Holtmann G, Talley N, Windsor J, Pirola R, Neale R.Summary and recommendations from the Australasian guidelines for the management of pancreatic exocrine insufficiency. Pancreatology. 2016 Mar-Apr;16(2):164-80. doi: 10.1016/j.pan.2015.12.006. Epub 2015 Dec 23. Review.
  22. Fernandes K, McLeod RL, Nikfarjam M, Weinberg L Intraoperative analysis of cross-talk inhibition between diaphragmatic and cardiac pacemakers. BMJ Case Rep. 2016 Jan 28;2016. pii: bcr2015213992. doi: 10.1136/bcr-2015-213992. No abstract available.
  23. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Nikfarjam M . Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Waddell N, Biankin AV, Grimmond SM. Genomic analyses identify molecular subtypes of pancreatic cancer. 2016 Mar 3;531(7592):47-52. doi: 10.1038/nature16965. Epub 2016 Feb 24.
  24. Gandy RC, Barbour AP, Samra J, Nikfarjam M, Haghighi K, Kench JG, Saxena P, Goldstein D. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. Med J Aust. 2016 Jun 20;204(11):419-22.
  25. Yeo D, Phillips P, Baldwin GS, He H, Nikfarjam M.Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Int J Cancer. 2017 May 1;140(9):2101-2111. doi: 10.1002/ijc.30615. Epub 2017 Feb 7.
  26. Kim SY, Weinberg L, Christophi C, Nikfarjam M.The outcomes of the pancreaticoduodenectomy in patients aged 80 or older. A systematic review and meta-analysis. HPB (Oxford). 2017 Mar 11. pii: S1365-182X(17)30054-0. doi: 10.1016/j.hpb.2017.01.018. [Epub ahead of print] Review.
  27. Wang J, Ma R, Churilov L, Eleftheriou P, Nikfarjam M, Christophi C, Weinberg L. The cost of perioperative complications following pancreaticoduodenectomy: A systematic review. 2017 Dec 19. pii: S1424-3903(17)30897-9. doi: 10.1016/j.pan.2017.12.008. [Epub ahead of print] Review.
  28. Wang J, Ma R, Eleftheriou P, Churilov L, Debono D, Robbins R, Nikfarjam M, Christophi C, Weinberg L. Health economic implications of complications associated with pancreaticoduodenectomy at a University Hospital: a retrospective cohort cost study. HPB (Oxford). 2017 Dec 13. pii: S1365-182X(17)31145-0. doi: 10.1016/j.hpb.2017.11.001. [Epub ahead of print]
  29. Balachandran VP, Łuksza M, Zhao JN, Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U, Senbabaoglu Y .. Nikfarjam M . S, Iacobuzio-Donahue CA, Wolchok JD, DeMatteo RP, Chan TA, Greenbaum BD, Merghoub T, Leach SD. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 2017 Nov 23;551(7681):512-516. doi: 10.1038/nature24462. Epub 2017 Nov 8
  30. Wang K, Huynh N, Wang X, Baldwin G, Nikfarjam M, He H. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. Int J Oncol. 2018 Jan;52(1):261-269. doi: 10.3892/ijo.2017.4193. Epub 2017 Nov 7.
  31. Weinberg L, Banting J, Churilov L, McLeod RL, Fernandes K, Chao I, Ho T, Ianno D, Liang V, Muralidharan V, Christophi C, Nikfarjam M The effect of a surgery-specific cardiac output-guided haemodynamic algorithm on outcomes in patients undergoing pancreaticoduodenectomy in a high-volume centre: a retrospective comparative study. Anaesth Intensive Care. 2017 Sep;45(5):569-580
  32. Weinberg L, Ianno D, Churilov L, Chao I, Scurrah N, Rachbuch C, Banting J, Muralidharan V, Story D, Bellomo R, Christophi C, Nikfarjam M. Restrictive intraoperative fluid optimisation algorithm improves outcomes in patients undergoing pancreaticoduodenectomy: A prospective multicentre randomized controlled trial. Anaesth Intensive Care. 2017 Sep;45(5):569-580.
  33. Issa Y, van Santvoort HC, Fockens P, Besselink MG, Bollen TL, Bruno MJ, Boermeester MA; Collaborators. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. HPB (Oxford). 2017 Nov;19(11):978-985. doi: 10.1016/j.hpb.2017.07.006. Epub 2017 Aug 15
  34. Huynh N, Wang K, Yim M, Dumesny CJ, Sandrin MS, Baldwin GS, Nikfarjam M, He H. Depletion of p21-activated kinase 1 up-regulates the immune system of APC∆14/+ mice and inhibits intestinal tumorigenesis. BMC Cancer. 2017 Jun 19;17(1):431. doi: 10.1186/s12885-017-3432-0
  35. Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Mol Oncol. 2017 Sep;11(9):1130-1142. doi: 10.1002/1878-0261.12078. Epub 2017 Jun 14.
  36. Chan J, Perini M, Fink M, Nikfarjam M. The outcomes of central hepatectomy versus extended hepatectomy: a systematic review and meta-analysis. HPB (Oxford). 2018 Feb 10. pii: S1365-182X(17)31195-4. doi: 10.1016/j.hpb.2017.12.008. [Epub ahead of print] Review.
  37. Kim SY, Fink MA, Perini M, Houli N, Weinberg L, Muralidharan V, Starkey G, Jones RM, Christophi C, Nikfarjam M.
  38. ANZ J Surg. 2018 May;88(5):E445-E450. doi: 10.1111/ans.14039. Epub 2017 Jun 7. Age 80 years and over is not associated with increased morbidity and mortality following pancreaticoduodenectomy.

  39. Nikfarjam M, Wilson JS, Smith RC; Australasian Pancreatic Club Pancreatic Enzyme Replacement Therapy Guidelines Working Group. Med J Aust. 2017 Aug 21;207(4):161-165
  40. Issa Y, van Santvoort HC, Fockens P, Besselink MG, Bollen TL, Bruno MJ, Boermeester MA; Collaborators inc Nikfarjam M. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. HPB (Oxford). 2017 Nov;19(11):978-985. doi: 10.1016/j.hpb.2017.07.006. Epub 2017 Aug 15
  41. Weinberg L, Ianno D, Churilov L, Chao I, Scurrah N, Rachbuch C, Banting J, Muralidharan V, Story D, Bellomo R, Christophi C, Nikfarjam M. Restrictive intraoperative fluid optimisation algorithm improves outcomes in patients undergoing pancreaticoduodenectomy: A prospective multicentre randomized controlled trial. PLoS One. 2017 Sep 7;12(9):e0183313. doi: 10.1371/journal.pone.0183313. eCollection 2017.
  42. Weinberg L, Banting J, Churilov L, McLeod RL, Fernandes K, Chao I, Ho T, Ianno D, Liang V, Muralidharan V, Christophi C, Nikfarjam M. The effect of a surgery-specific cardiac output-guided haemodynamic algorithm on outcomes in patients undergoing pancreaticoduodenectomy in a high-volume centre: a retrospective comparative study. Anaesth Intensive Care. 2017 Sep;45(5):569-580.
  43. Wang K, Huynh N, Wang X, Baldwin G, Nikfarjam M, He H. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. Int J Oncol. 2018 Jan;52(1):261-269. doi: 10.3892/ijo.2017.4193. Epub 2017 Nov 7.
  44. Wang J, Ma R, Eleftheriou P, Churilov L, Debono D, Robbins R, Nikfarjam M, Christophi C, Weinberg L. Health economic implications of complications associated with pancreaticoduodenectomy at a University Hospital: a retrospective cohort cost study. HPB (Oxford). 2018 May;20(5):423-431. doi: 10.1016/j.hpb.2017.11.001. Epub 2017 Dec 14.
  45. Wang J, Ma R, Churilov L, Eleftheriou P, Nikfarjam M, Christophi C, Weinberg L. Pancreatology. The cost of perioperative complications following pancreaticoduodenectomy: A systematic review. 2018 Mar;18(2):208-220. doi: 10.1016/j.pan.2017.12.008. Epub 2017 Dec 19. Review.
  46. Nadebaum DP, Lee ST, Nikfarjam M, Scott AM. Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature. World J Nucl Med. 2018 Jul-Sep;17(3):195-197. doi: 10.4103/wjnm.WJNM_38_17.
  47. Lee NH, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology. 2018 Oct;18(7):705-716. doi: 10.1016/j.pan.2018.07.011. Epub 2018 Aug 1. Review
  48. Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol. 2018 Sep 7;24(33):3709-3723. doi: 10.3748/wjg.v24.i33.3709. Review

  49. Maharaj AD, Ioannou L, Croagh D, Zalcberg J, Neale RE, Goldstein D, Merrett N, Kench JG, White K, Pilgrim CHC, Chantrill L, Cosman P, Kneebone A, Lipton L, Nikfarjam M, Philip J, Sandroussi C, Tagkalidis P, Chye R, Haghighi KS, Samra J, Evans SM. Monitoring quality of care for patients with pancreatic cancer: a modified Delphi consensus. HPB (Oxford). 2018 Oct 10. pii: S1365-182X(18)33948-0. doi: 10.1016/j.hpb.2018.08.016. [Epub ahead of print]
  50. Cox DRA, Fong J, Liew CH, Goh SK, Yeoh M, Fink MA, Jones RM, Mukkadayil J, Nikfarjam M, Perini MV, Rumler G, Starkey G, Christophi C, Muralidharan V Emergency presentations of acute biliary pain: changing patterns of management in a tertiary institute. ANZ J Surg. 2018 Dec;88(12):1337-1342. doi: 10.1111/ans.14898. Epub 2018 Nov 9
  51. Sharafi G, He H, Nikfarjam M Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer. J Pancreat Cancer. 2019 Jan 25;5(1):1-7. doi: 10.1089/pancan.2018.0019. eCollection 2019. Review.
  52. Wang K, Baldwin GS, Nikfarjam M, He H. The anti-tumour effects of all-trans retinoic acid and its synergism with gemcitabine are associated with down-regulation of p21-activated kinases in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2019 Mar 7. doi:

Books and Book Chapters

Book

  1. Nikfarjam M. The Effect of laser induced thermal ablation on liver tumours. Publisher: VDM Verlag (July 2008)

Book Chapter

  1. Nikfarjam M & Ponsky J Atlas of the Pancreas. Chapter 7. Endoluminal approaches to pancreatic pseudocyst. American College of Surgeons. 2009 (In Press)
  2. Nikfarjam M & Ponsky J. Endoluminal treatments for gastroesophageal reflux disease. Cameron's Textbook of Surgery 2009
  3. Nikfarjam M & Marks J. Future of NOTES. Cameron's Textbook of Surgery 2009
  4. A Hadj & Nikfarjam M Post-procedural Considerations: Standard patient recovery practices & Identification of post-procedural complications. Principles of Flexible Endoscopy 2012 (in Press)
  5. Burnett D & Nikfarjam M Pancreatic cancer. Smith Textbook of Surgery 4th edition 2019
  • ANZ HPBA
  • Australasian Pancreatic Club
  • Pancare Foundation
  • SSAT
  • APA
  • ASGE
  • AHPBA
  • GESA
  • IHPBA
  • AAS
  • RACS
  • SAGES